|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Hedi Ben Brahim||CEO & Director||312k||S.O.||1981|
|Mr. Jean-Philippe Del||VP & CFO||S.O.||S.O.||1981|
|Dr. Eric Quemeneur Ph.D.||Exec. VP & Chief Scientific Officer||S.O.||S.O.||1965|
|Ms. Elisabetta Castelli||Director of Investor Relations||S.O.||S.O.||S.O.|
|Mr. John Felitti J.D., LLM||VP, Gen. Counsel & Corp. Sec.||S.O.||S.O.||1970|
|Lucie Larguier||Director of Corp. Communications & IR||S.O.||S.O.||S.O.|
|Ms. Gaelle Stadtler||VP & Director of HR||S.O.||S.O.||1983|
|Mr. Philippe Slos||Head of Preclinical Regulatory Laboratory||S.O.||S.O.||S.O.|
|Dr. Maud Brandely-Talbot M.D., Ph.D.||VP of Medical Affairs & Chief Medical Officer||S.O.||S.O.||1954|
|Mr. Steven H. Bloom R.Ph.||VP & Chief Bus. Officer||S.O.||S.O.||1962|
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
L’ISS Governance QualityScore de Transgene SA en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..